Explanipedia

#728 Predicting individual patient response to corticosteroids in IgA nephropathy: a secondary analysis from the TESTING cohort Open

Mark Canney, Sana Shan, Lee Er, Laurent Billot, Jialin Han , et al. · 2025

Background and Aims Corticosteroids are an effective treatment for IgA nephropathy but are associated with considerable adverse events. The TESTING clinical trial showed an average treatment effect of a 47% relative risk reduction in the p…

#2859 <b>ORIGIN 2b: changes in Gd-IgA1 and eGFR after discontinuation of atacicept treatment in IgA nephropathy</b> Open

Jonathan Barratt, Sean Barbour, Robert Brenner, Necmi Eren, Jürgen Floege , et al. · 2025

Background and Aims IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with up to 50% of patients progressing to ESKD or death within 20 years. The cytokines B-cell Activating Factor (BAFF) and A Proliferation-…

Sex Differences Across Corticosteroid Response and Outcomes in IgA Nephropathy Open

Dana Kim, Mark Woodward, Jicheng Lv, Michelle Hladunewich, Vivekanand Jha , et al. · 2025

Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy? Open

Luxcia Kugathasan, Pritha Dutta, Massimo Nardone, Vikas S. Sridhar, David J.T. Campbell , et al. · 2025

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN Open

Vivekanand Jha, Richard Lafayette, Sean Barbour, Robert Brenner, Kerry Cooper , et al. · 2025

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY Open

Uptal D. Patel, Jürgen Flöge, Jonathan Barratt, Richard Lafayette, Brian S. Schwartz , et al. · 2025

Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy Open

Jingyi Li, Jicheng Lv, M.G. Wong, Sufang Shi, Jincan Zan , et al. · 2024

#123 Impact of atacicept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study Open

Jürgen Floege, Jonathan Barratt, Bart Maes, Kerry Cooper, Celia J. F. Lin , et al. · 2024

Background and Aims Patients with IgA nephropathy (IgAN) and persistent hematuria during follow up have a greater decline in renal function than those with minimal or no hematuria, while hematuria resolution has been independently associat…

#425 Felzartamab (anti-CD38) in patients with IgA Nephropathy—interim results from the IGNAZ study Open

Jürgen Floege, Richard Lafayette, Jonathan Barratt, Brian S. Schwartz, Paul T Manser , et al. · 2024

Background and Aims Most patients with IgA nephropathy (IgAN) will progress to kidney failure within 10-15 years of diagnosis. Sustained proteinuria is the best predictor of adverse long-term kidney outcomes and is a surrogate marker for e…

#812 Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis Open

Richard Lafayette, Bart Maes, Rubeen Israni, Celia J. F. Lin, Xuelian Wei , et al. · 2024

Background and Aims IgA nephropathy (IgAN), the most common primary glomerulonephritis and a significant contributor to ESKD worldwide, is characterized by elevated serum levels of galactose-deficient IgA1 (Gd-IgA1). The production of Gd-I…

The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy Open

Dana Kim, Jicheng Lv, Michelle Hladunewich, Vivekanand Jha, Lai Seong Hooi , et al. · 2024

Reduced-dose methylprednisolone is effective in improving kidney outcomes in high risk IgAN; however, it is associated with a modestly higher number of SAEs compared to placebo.

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY Open

Jonathan Barratt, Bart Maes, Celia J. F. Lin, Xuelian Wei, Sean Barbour , et al. · 2024

IgA nephropathy (IgAN) is the most common primary glomerulonephritis and a significant contributor to ESKD worldwide. Hematuria is an indicator of IgAN activity representing active glomerulonephritis and resolution is associated with impro…

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY Open

Jonathan Barratt, Bart Maes, Rubeen Israni, Xuelian Wei, Jürgen Floege , et al. · 2024

IgA nephropathy (IgAN) is the most common primary glomerulopathy worldwide, with up to 50% of patients progressing to ESKD or death within 20 years.(1,2) B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) play an i…

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy Open

Richard Lafayette, Sean Barbour, Rubeen Israni, Xuelian Wei, Necmi Eren , et al. · 2024

Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patient…

Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease Open

Jie Zheng, Y. Zhang, Humaira Rasheed, V.A. Walker, Yasuhiko Sugawara , et al. · 2024

Background: This study was to systematically test whether previously reported risk factors for chronic kidney disease (CKD) are causally related to CKD in European and East Asian ancestries using Mendelian randomization. Methods: A total o…

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial Open

Vibeke Strand, David Jayne, Audra Horomanski, Huibin Yue, Pirow Bekker , et al. · 2023

#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN Open

Richard Lafayette, Bart Maes, Celia J. F. Lin, Sean Barbour, Richard Phoon , et al. · 2023

Background and Aims IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Galactose-deficient IgA1 (Gd-IgA1), anti-Gd-IgA1 autoantibodies (anti-Gd-IgA1), and IgA-IgG-containing immune complexes (ICs) are centra…

Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report Open

Rohini Naipaul, Catherine Marques, Jenny Ng, Sean Barbour, Christine Lo , et al. · 2023

Purpose of Program: Glomerulonephritis (GN) is a group of rare kidney diseases that is increasingly being managed with higher cost immunosuppressive (IS) agents in Canada. Ontario Health’s Ontario Renal Network (ORN) oversees the managemen…

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Open

Jonathan Barratt, Richard Lafayette, Jens Kristensen, Andrew Stone, Daniel Cattran , et al. · 2022

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy Open

Jicheng Lv, Muh Geot Wong, Michelle Hladunewich, Vivekanand Jha, Lai Seong Hooi , et al. · 2022

ClinicalTrials.gov Identifier: NCT01560052.

Editorial Board Open